Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has continued to expand coverage for Ryoncil® (remestemcel-L), the ...

Synchronized drawdowns create opportunities to buy stocks that have been unfairly punished. Check out two dividend ...

Deckers Outdoor Corporation's resilient brands like Uggs & Hoka make it a strong medium-term investment despite price ...